Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Codabakalner in Fragile X Syndrome and Autism Spectrum Disorders
NCT07439510Phase 3Not yet recruiting
- Sponsor
- Spinogenix
- Start
- Dec 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Fragile X syndrome (FXS) and Autism Spectrum Disorder (ASD) (4 arms), sponsored by Spinogenix. Primary endpoints: Total Cognition Composite Change Sensitive Score from the NIH Toolbox Cognitive Battery at 28 days and Vineland Adaptive Behavior Scales Adaptive Behavior Composite Score at 12 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
Fragile X syndrome (FXS)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07439510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439510.